ALK and non-small cell lung carcinoma: Finally, longitudinal monitoring of ctDNA revealed inferior PFS in ALK-positive NSCLC patients with detectable ctDNA before initiation of treatment, but also showed that an increase in ctDNA levels was prognostic of progression, preceding the radiologic determination of PD by 69 days [66].